Novel application of selepravastatin

Abstract

The invention discloses a new application of selepravastatin, namely an application of selepravastatin in preparation of a medicine for treating nephropathy. The application has the advantages that anew medicine for treating the nephropathy is provided, the effect of treating the membranous nephropathy is achieved through the immune effect, and finally animal experiments prove that the selaprivapeptide can reduce total urinary protein, urinary albumin and systolic pressure of membranous nephropathy model animals, so that the selaprivapeptide is a new immune agent and a novel therapeutic meansfor treating the membranous nephropathy.

Description

technical field [0001] The invention belongs to the technical field of medicine, and specifically relates to a new application of selepravatide. Background technique [0002] Membranous nephropathy (MN) accounts for 20% to 35% of primary nephrotic syndrome (NS), and is one of the common pathological types of nephrotic syndrome at home and abroad. MN is a pathological diagnosis. There are often numerous and regular immune complexes on the epithelial side of the glomerular basement membrane (GBM) as its pathological feature. According to the etiology, it can be divided into idiopathic membranous nephropathy (IMN) and secondary membranous nephropathy (SMN). IMN immunofluorescence is often dominated by IgG4, with c3 in a granular form along the GBM. If the immunofluorescence is dominated by IgG1 and (or) IgG2, and other conditions such as C1q and (or) C4 deposition appear, SMN should be carefully excluded. The current treatment options are mainly divided into conservative tre...

Images